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Millions of young people are not immunized in low- and middle-income (LMI) countries
because of low vaccine availability resulting from inefficiencies in cold supply chains. We create
supply chain network design and distribution models to address the unique characteristics and
challenges facing vaccine supply chains in LMI countries. Themodels capture the uncertainties
of demand for vaccinations and the resulting impacts on immunization, the unique challenges
of vaccine administration (such as open vial wastage), the interactions between technological
improvements of vaccines and immunizations, and the trade-offs between immunization cov-
erage rates and available resources. The objective is to maximize both the percentage of fully
immunized children and the vaccine availability in clinics. Our research examines how these
two metrics are affected by three factors: number of tiers in the supply chain, vaccine vial size,
and new vaccine technologies. We tested themodel using Niger’s Expanded Program on Immu-
nization, which is sponsored by the World Health Organization. We make many observations
and recommendations to help LMI countries increase their immunization coverage.
1 Introduction
This study develops stochastic models to optimize the cold supply chains for distribution of pediatric vaccines in low-
and middle-income (LMI) countries. We use these models to estimate how supply chain structure, vaccine vial size,
and new vaccine technologies impact vaccine availability and, consequently, vaccine coverage rates in LMI countries.
This research represents a large step forward because, to our knowledge, all previous studies of this topic use either
deterministic models or simulation. We demonstrate how our stochastic model provides more accurate solutions that
lead to higher percentages of fully immunized children (FIC), which is a key metric in this field.
Vaccines have been used for more than 50 years to prevent childhood diseases. In 1974, the World Health
Organization (WHO) launched the Expanded Program on Immunization (EPI) with the goal of immunizing every
child and pregnant woman around the world (WHO 1974). The Global Vaccine Action Plan (GVAP), launched by
the World Health Assembly in 2011, established a target for immunization coverage of 90% for EPI vaccines by 2020
(WHO 2014). Despite the success of GVAP over the last few years, in 2018 more than one in ten children worldwide
did not receive vaccines for measles, diphtheria, or tetanus (WHO 2019a). In Niger, the focus of our case study, the
immunization coverage for the diphtheria-tetanus-pertussis (DTP) vaccine was 85% in 2017, and 75% in 2018 (WHO
2019a).
We acknowledge that social, political, and economic factors lead to low vaccination coverage, but we focus on those
factors within the supply chain, following Kraiselburd and Yadav (2012)’s call to action for Supply Chain Management
researchers to help improve global health supply chains for medicines, vaccines, and health technologies. Problems we
consider include exposure to temperatures outside the required range of 2°C - 8°C, expiration, and physical damage.
Other logistical challenges that cause vaccine wastage in LMI countries are the lack of an adequate road network, the
time required to reach rural health facilities, the vaccine overstock at the national central store arising from the inability
of placing smaller orders more frequently, etc. The case study of Section 5 reports a number of observations and
provides recommendations for the development of policies and guidelines to facilitate the achievement of EPI targeted
immunization coverage rates in Niger.
1.1 Background on Vaccine Supply Chains in LMI Countries
A typical EPI vaccine distribution network consists of four tiers: a national central store, regional stores, district
stores, and clinics. United Nations Children’s Fund (UNICEF) replenishes the inventory of the central store annually.
Vaccines are shipped from the central store to the regional stores and from the regional stores to district stores using
trucks. Refrigerated trucks are used for long distances. The district stores use cars and motorcycles to ship vaccines
to the clinics where children are vaccinated. The number of tiers in the supply chain might be greater or smaller
than four, depending on the country. For example, Vietnam uses one additional tier between the regional and district
stores. However, every supply chain has a central, national-level store where vaccines are inventoried for delivery to
downstream supply chain members.
Cold supply chains with four or more tiers have lower transportation costs, but higher inventory processing/holding
costs, than do supply chains with only three tiers. The smaller number of facilities in a three-tier supply chain leads to
fewer broken vials (since vaccines are handled fewer times), compared to supply chains with four or more tiers. These
trade-offs influence public health administrators’ evaluation of how changes to the supply chain structure would impact
costs and vaccine availability.
1.2 Research Questions
The cold supply chain plays a crucial role in delivering vaccines in LMI countries. These supply chainswere established
decades ago and were designed to deliver only six vaccines. During the last two decades, additional vaccines, including
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hepatitis B (HepB), hemophilus influenza type B (Hib), pneumococcal conjugate, rotavirus, and human papillomavirus
were added to the schedule (WHO 2019b). With the expansion of immunization programs and the introduction of
new vaccines, these supply chain structures have become outdated and strained beyond their capacity. For example, a
four-tier supply chain made sense 40 to 50 years ago because communication systems were underdeveloped. However,
now a four-tier supply chain leads to vaccine overstock (because inventories are maintained in every store in every
tier), which increases waste from damages, expiration, etc. New and advanced communication channels enable public
health administrators to track inventories in real-time, thereby rendering so many administrative layers unnecessary.
Local health centers can now directly call the central stores to request inventories, bypassing regional or district stores
(Humphreys 2011). This observation motivates our first research question: (R1) How does changing the number of
tiers in the supply chain affect vaccine availability?
Vaccines can be manufactured in a variety of vial sizes, typically 1, 5, 10, or 20-doses (see Table 1). We use the
term vaccine packaging to refer to the number of doses per vaccine vial. A large vaccine vial with many doses uses
less storage space per dose than does a smaller vaccine vial; thus, the corresponding inventory holding cost per dose
is less. However a large-dose vaccine vial has more open vial wastage (OVW) than does a small-dose vaccine vial.
These observations motivate our second research question: (R2) How does vaccine vial size affect the immunization
coverage rates?
Table 1 Vaccine characteristics.
Vaccine Nr. of doses Volume Diluent volume Nr. of doses Storage
type per vial (cc/dose) (cc/dose) in regimen
BCG 20 1.2 0.7 1 Refrigerator/freezer
Tetanus 10 3.0 3 Refrigerator
Measles 10 2.1 0.5 2 Refrigerator
Oral Polio 20 1.0 4 Freezer
Yellow Fever 10 2.5 6.0 1 Refrigerator/freezer
DTP-HepB-Hib 1 16.8 3 Refrigerator
According to UNICEF, a pressing problem in LMI countries is vaccine shortages, which diminish the ability to
meet vaccination demand. Many shortages occur because of the increased number and types of vaccines flowing in the
supply chain: some countries have doubled the types of vaccines offered since the 1970s (Humphreys 2011). Larger
populations also contribute to the increased volume in the supply chain. Furthermore, new vaccines have become
bulkier. For example, dual-chamber vaccine injection devices are designed to simplify the reconstitution of vaccines
before administration by pairing the vaccine and the diluent in the same unit. This alignment reduces wastage from
OVW and other adverse events (Wedlock et al. 2018), but dual-chamber devices are more expensive and use more
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storage space per dose than do the traditional EPI vaccines, which come in 10- and 20-dose vials (Wedlock et al. 2018).
Most vaccines are stored at temperatures between 2°C and 8°C. The introduction of new vaccines plus the increased
storage requirements per dose for dual-chamber devices require additional cold storage space. Countries that do not
have the means to expand cold storage capacity postpone the introduction of new vaccines. A new technological
advancement, thermostable vaccines, can resist heat, so they do not need refrigeration. (The term vaccine presentation
represents both dual-chamber and thermostable vaccines.) Such a technology increases the shelf life of vaccines
without consuming cold storage space. Hence, this innovation improves vaccine availability and reduces wastage.
However, this new technology is expensive. These observations motivate our third research question: (R3) How does
using new vaccine presentations affect immunization coverage rates?
We develop a stochastic optimization model to address the research questions. The objective is to maximize the
percentage of FIC and the vaccine availability in clinics, which is measured by the supply ratio (SR). A fully immunized
child receives every required dose of EPI vaccines specified by the vaccine regimen before turning five years old. The
percentage of FIC measures the efficiency of the supply chain and of the public educational campaigns. SR measures
only the efficiency of the supply chain because it represents the percentage of children that could be vaccinated using
the inventory available in all clinics. Thus, SR is equivalent to inventory fill rate used in the supply chain literature. We
use the term SR to facilitate comparison of our results to others’ who study vaccine coverage. Ourmodel determines the
need for storage and transportation capacity at each location, given the uncertain nature of the demand for vaccinations.
We develop a case study using real-life data from Niger to evaluate the performance of the model. We make a number
of observations, and we provide recommendations about vaccine distribution strategies and administration policies
which lead to increases in FIC and SR.
1.3 Research Contributions
Only a few papers in the literature analyze the impacts of supply chain decisions on the immunization coverage
rate of pediatric vaccines in LMI countries (Assi et al. 2013, Azadi et al. 2019, Chen et al. 2014, Lee et al. 2012,
2017, Wedlock et al. 2018). The existing research is limited in scope because either it conducts economic analyses
of vaccination programs under different supply chain designs, or it proposes deterministic optimization models to
maximize immunization coverage. Furthermore, previous models do not consider the compound effects of the
numbers of tiers in the supply chain, the vaccine vial size, and the introduction of new vaccine technologies on vaccine
availability at clinics. Our research contributes to the literature in the following ways:
• We propose a data-driven, stochastic optimizationmodel that considers the randomnature of demand for vaccines,
which among other consequences leads to high OVW, which reduces immunization coverage.
• Our model facilitates the evaluation of how the number of tiers of the cold supply chain, the vaccine vial size,
and the new vaccine technologies impact immunization coverage rates.
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• Our model is validated using real-life data from Niger. We present a number of observations and make
recommendations that will improve the performance of the country’s cold supply chain.
This study is organized as follows: Section 2 presents a review of the relevant literature and identifies a research
gap. We present the model and corresponding solution approach in Section 3 and outline the case study from Niger
in Section 4. Then, Section 5 summarizes the results and provides managerial insights. A summary of the results and
suggestions for future work are in Section 6.
2 Literature Review
We first briefly summarize previous works on perishable inventory in general. Then we narrow our focus to vaccine
supply chains.
Most works on perishable inventory address food, especially fresh produce, as shown in many surveys (Bakker et al.
2012, Dave 1991, Goyal and Giri 2001, Karaesmen et al. 2011, Li et al. 2010, Nagurney et al. 2010, Nahmias 1982,
Raafat 1991). One outlier is Zhou et al. (2011), who optimize a periodic review inventory system for platelets used by
hospital blood transfusion centers. This is somewhat similar to our environment, being based in public health, but the
study only considers one party, not the entire supply chain.
We briefly discuss other studies that consider the larger perishable food supply chain. Blackburn and Scudder
(2009) recommend a supply chain that is responsive from post-harvest to initial storage, then efficient beyond that.
Ketzenberg et al. (2015) evaluate the use of sensors affixed to inventory to collect time and temperature information of
perishables as they flow through a supply chain. Gaulkler et al. (2020) address a similar environment to determine the
optimal transportation mode for each link. Govindan et al. (2014) study distribution in a two-echelon location-routing
problemwith time-windows. Theirmulti-objectivemodel reduces traditional business costs plus those fromgreenhouse
gas emissions. A key distinction is that most studies of supply chains for perishable products have traditional business
objectives of minimizing cost or maximizing revenues, which generally are secondary in public health applications.
Duijzer et al. (2018a) survey the literature on vaccine supply chains. Most such studies focus on supply chain
problems for one of two groups of vaccines: (i) seasonal vaccines, such as influenza, and (ii) nonseasonal ones, such
as pediatric vaccines. Only a few works in the literature propose models to design a cold supply chain network
for influenza vaccines (Hovav and Tsadikovich 2015). Some studies address the influenza vaccine’s supply chain
contracting problem (Chick et al. 2008, Dai et al. 2016). Other studies consider vaccine allocation decisions during
pandemics (Duijzer et al. 2018b, Westerink-Duijzer et al. 2020). The focus of our research is nonseasonal vaccines.
A number of studies of nonseasonal vaccines consider the distribution network design for pediatric vaccines in
LMI countries. Most of these works conduct an economic analysis of a proposed distribution network design and
compare the results with conventional designs (see Riewpaiboon et al. (2015)). Other works propose discrete event
simulation models to evaluate the performance of specific vaccine distribution networks. Work by Assi et al. (2011,
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2013), Haidari et al. (2013), Brown et al. (2014), Haidari et al. (2015), Lee et al. (2015, 2016, 2017), Mueller et al.
(2016), and Wedlock et al. (2018) use the Highly Extensible Resource for Modelling Event-Driven Supply Chains
(HERMES) software to study the supply chains in Niger, India, and Benin. For example, Haidari et al. (2013) use
HERMES to evaluate how adding stationary storage and transportation capacity impacts vaccine availability at clinics
in Niger. Several other papers use HERMES to explore the impact of different vaccine distribution strategies on supply
chain costs and vaccine availability in clinics (Assi et al. 2013, Brown et al. 2014, Haidari et al. 2015, Lee et al. 2015).
In contrast, we propose a stochastic optimization model for supply chain decisions under uncertainty.
Some papers useHERMES to explore the impact of vaccine packagingon supply chain costs and vaccine availability
at clinics), and other papers use Monte Carlo simulation (Dhamodharan and Proano 2012). Assi et al. (2011) simulate
the supply chain of EPI vaccines in Niger. The authors analyze the performance of Niger’s vaccine distribution network
if the measles vaccine vial size were to change from 10-dose to 5-, 2-, or 1-dose. A recent study by Azadi et al.
(2019) evaluates the trade-offs between using a single, fixed vial size for each vaccine and using a combination of
vial sizes. Azadi et al. (2019) assume a two-tier supply chain consisting of the central store and the clinics. Clinics
observe the daily stochastic demand and decide when and which vaccine vial to open to minimize OVW. By focusing
on optimizing the daily operational decisions of inventory management and vaccine administration, they conclude that
using a combination of 1- and multi-dose vials leads to improved performance of the cold supply chain and, thus, to
increased vaccine availability. Our models extend the stochastic optimization model developed by Azadi et al. (2019)
by evaluating the impact of strategic decisions (i.e., changing the number of tiers in the supply chain) and of planning
decisions (i.e., changing vaccine packaging) on the level of FIC and of SR in Niger.
Lee et al. (2017) use HERMES to evaluate the economic impacts of thermostable vaccines, and Wedlock et al.
(2018) use HERMES to examine how the measles-rubella vaccine’s dual-chamber injection device effects OVW and
vaccine availability. The structure of the supply chain is fixed in both studies (as it is for all that use HERMES), and
vaccines are pushed down the supply chain to meet demand. Our optimization model, in contrast, can specify an
optimal redistribution among all vaccines of the resources that become available when a new vaccine presentation is
implemented for a subset of vaccines. Furthermore, in addition to maximizing vaccine availability SR, our objective
maximizes the percentage of FIC. Maximizing the percentage of FIC requires clinics to maintain a balanced inventory
of vaccines, which influences decisions in the supply chain.
Chen et al. (2014) use the estimated mean demand for vaccines to evaluate the performance of three- and four-tier
supply chains. Relying solely on the mean demand can lead to inefficient decisions in the cold supply chain and may
reduce the study’s realism. For example, Chen et al. (2014) found that the performance of three- and four-tier supply
chains of Niger does not impact the number of FIC. Our numerical analysis indicates that the three-tier supply chain
leads to higher FIC than does the four-tier supply chain. This finding through stochastic optimization provides further
evidence of the observation Assi et al. (2013) made through simulation.
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3 Model Description and Solution Approach
This section establishes a modeling framework for the cold supply chain that delivers vaccines from an LMI country’s
point of entry to the clinics that administer vaccines to children. The objective is to maximize the percentage of FIC by
increasing vaccine availability at clinics. The availability of vaccines is represented by SR, the proportion of demand
that is met from the available inventory. The network design of the cold supply chain, the vaccine vial size, and the
vaccine presentation impact vaccine availability, hence we combine FIC and SR to form the appropriate objective to
answer our research questions.
This section begins by presenting the assumptions, which are motivated by practices in the field. After describing
the conceptual framework, we present the mathematical model.
3.1 Assumptions
The WHO and other nonprofit organizations deliver pediatric vaccines to LMI countries. These organizations work
closely with the countries’ governmental officials to make manufacturer selections and procurement decisions. We
assume that these decisions have been made so that we can focus on a receiving country’s cold supply chain network,
which begins at the nation’s central store (where vaccines are received) and ends at the clinics around the country.
Practices in Niger and the standards of the EPI cold supply chain inspire the following assumptions:
• The cold supply chain delivers only EPI vaccines.
• The planning horizon is one year, and the planning period is one month.
• The vaccine vial size represents the number of doses per vial. Vial size is fixed in our analysis of research
questions R1 and R3.
• Manufacturing capacity is not a bottleneck.
• Since vaccines have different characteristics, some can be stored in refrigerators and freezers, such as Bacillus
Calmette–Guérin (BCG), and others must be stored in refrigerators, like the measles vaccine.
• Vaccines that are freeze-dried before shipping are restored prior to injection with a diluent. The diluent is
refrigerated the day before reconstitution so that it is the same temperature as the freeze-dried vaccine.
• Some of the EPI vaccines require one dose for complete immunization, and others require multiple doses at
different stages of childhood, such as the measles vaccine. The number of doses required to immunize children
fully is the vaccine regimen.
• The expected OVW in clinics depends on the expected number of patient arrivals and on the vaccine vial sizes.
OVW rates are calculated offline using this information.
• The demand for vaccines in storage facilities is zero.
• The existing cold supply chain has limited refrigeration and freezer capacity.
• The supply chain has the required transportation capacity to deliver vaccines.
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3.2 Conceptual Framework
This section presents the structure of the mathematical model and describes the constraints intuitively.
The goal of the optimization model is to maximize the percentage of FIC and the vaccine availability, measured
via SR, in LMI countries during the planning horizon. Considering both objectives provides a clearer picture of the
EPI’s effectiveness.
The decision variables are the number of vaccine vials (and their sizes, if appropriate) shipped from an upstream
store to a downstream store or clinic. These determine the inventory of vaccines stored at each location, the amount of
demand satisfied at each clinic, and the number of FIC at each clinic.
The constraints are categorized as follows.
1) Inventory balance constraints: The number of vaccine vials in a store in period t depends on the store’s
inventory from the previous period and on the amount shipped (both in and out) during period t.
2) Capacity constraints: The number of vaccines inventoried in a store is limited by the number and the capacity
of its refrigerators and freezers.
3) Inventory initialization constraints: The inventory of vaccine vials in stores at the beginning of the planning
horizon is zero.
4) Storage differentiation constraints: The storage space for a vaccine depends on the vial size and the vaccine
type.
5) FIC constraints: The number of FIC is limited by the number of vaccines available at the clinics.
6) Demand constraints: The probability of vaccinating every child who visits a clinic must be higher than a
specified threshold level.
Whereas the decision to use a three- or four-tier supply chain is a strategic decision, inventory replenishment and
transportation scheduling are operational decisions. Our model integrates these different types of decisions under
uncertainty. The demand for vaccination at a clinic is modeled as a stochastic parameter, and the demand constraint
is modeled as a chance constraint. We use the comprehensive data analysis in Azadi et al. (2018) to develop the
distribution of demand.
We model both a four-tier supply chain and a three-tier supply chain for distribution of vaccines. Both models
are then updated to consider the implications of using different vaccine vial sizes and of using a new technology that
impacts vaccine presentation. Both models are stochastic linear programs that maximize the percentage of FIC and the
vaccine availability SR.
3.3 Mathematical Model
Our model increases vaccine availability by identifying the appropriate number of tiers in the supply chain and by
developing a plan for both inventory replenishment and transportation of vaccines.
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Let Gt = (J,A) be a directed graph that represents the vaccine supply chain network at time period t during a
planning horizon of length T (t ∈ T ). In this graph, J is the set of nodes, and A is the set of arcs. Let J(⊂ J)
represent the set of clinics and I represent the set of vaccine types. Let ∆ijt represent the stochastic demand for
vaccine i ∈ I at a clinic j ∈ J during period t ∈ T , and let µijt represent the corresponding expected value. Note
that ∆ijt follows a Poisson distribution because it represents the number of patients arriving at a clinic in period t.
The distribution of ∆ijt can be approximated with a Normal distribution ∆¯ijt because µijt > 10 (Devore 2011). Since
demand for vaccinations is positive, we approximate it using a truncated Normal random variable ∆ijt ≈ max{0, ∆¯ijt }.
Let xR
ijt
and xF
ijt
represent the number of vaccines refrigerated and frozen at a clinic in period t. Meeting all demand
for vaccinations would require
xRijt + x
F
ijt ≥ ∆ijt, ∀i ∈ I, j ∈ J, t ∈ T . (1)
This deterministic constraint cannot always be met in LMI countries, given their capacity limitations and the cost of
maintaining a high inventory level. Thus, these constraints are softened by requiring that they be satisfied for only a
specified percentage of combinations of i, j, and t. Let β be the risk parameter selected by clinic j ∈ J for vaccine i ∈ I.
The nominal value of this parameter, 10%, is motivated by Global Alliance for Vaccines and Immunizations’ target
immunization coverage of 90% for EPI vaccines (WHO 2014). We update constraints (1) using chance constraints (2),
which indicate that the number of vaccines available in every time period should be greater than or equal to demand in
at least (1 − β)% of cases:
P
(
xRijt + x
F
ijt ≥ ∆ijt
)
≥ (1 − β) ∀i ∈ I, j ∈ J, t ∈ T . (2)
Chance Constraint Programming (CCP) formulates an optimization problem with a probabilistic constraint. CCP
has been used to model optimization problems which arise in a number of fields, such as healthcare (Beraldi et al.
2004), financial risk management (Donkor and Duffey 2013), and renewable energy generation (Lubin et al. 2016),
among others. A complete CCP model formulation, which we refer to as formulation (P), is presented in Appendix A,
along with a list of the decision variables and the parameters.
The following succinct formulation of (P) simplifies the exposition of the algorithm presented in §3.4. This
formulation uses a single decision vector x ∈ X to denote collectively all the decision variables described in Appendix
A. The objective function, F(x), maximizes the percentage of FIC and the vaccine availability SR by summing these
two with a weighting factor. To find the number of FIC, we calculate the number of children who received every
dose specified by the vaccine regimen. Vaccine availability represents the total number of doses available in clinics.
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Constraints (7b)-(7l) in Appendix A, summarized in §3.2, define the feasible region X:
(P) : max
x∈X
F(x) (3a)
s.t. : P
(
Gijt (x,∆ijt ) ≥ 0
)
≥ (1 − β), ∀i ∈ I, j ∈ J, t ∈ T , (3b)
where
Gijt (x,∆ijt ) = x
R
ijt + x
F
ijt − ∆ijt .
F(x) is a continuous real valued function, and function Gijt (x,∆ijt ), which represents either unmet demand or
excess inventory in period t, is measurable for every x ∈ Rn and continuous for every feasible ∆ijt . Let υ
∗ be the
optimal objective value of (P). We assume that υ∗ is bounded and that the feasible region X is non-empty.
Our model does not have budget constraints, but it does consider transportation and storage capacity constraints.
This is in line with other models of humanitarian supply chains that focus on improving human lives and well-being,
rather than on minimizing costs or maximizing profits (Balcik et al. 2015, Beamon and Balcik 2008, McCoy and Lee
2014).
3.4 Solution Approach
CCP models are difficult to solve because of (i) the non-convexity of the feasible set defined by chance constraints, and
(ii) the inability to compute the probability of satisfying chance constraints (arising from the computational challenge of
multi-dimensional integration) (Kim et al. 2015, Van Ackooij et al. 2011). However, there are a few exceptions to this
observation. For example, researchers have developed computationally tractable approximations of CCP models with
single chance constraint(s) when the distribution of uncertain parameters belongs to a family of logarithmically concave
distributions (Geletu et al. 2013, Küçükyavuz 2012).∗ In general, the development of a tractable approximation to a
chance constraint is not an option (Henrion 2004). This is why many researchers use the sample average approximation
(SAA) method to solve CCP models.
SAA is a scenario-based approach to solving stochastic optimization problems. The scenarios considered are
generated via Monte Carlo simulation. Each scenario represents a realization of problem parameters drawn from
empirical distributions. These realizations are used to develop a corresponding deterministic equivalent formulation
(DEF) (Jiang and Guan 2016, Pagnoncelli et al. 2009). The DEF guarantees that the number of instances that do not
satisfy constraints (1) in the independent trials of random sampling is below a certain level.
Because the random parameter ∆ijt follows a truncated Normal distribution, a closed-form representation of the
chance constraints cannot be derived. Instead, SAA is used to solve (P).
∗The interest reader may consult Nemirovski (2012)’s survey of scenario-based and computationally tractable approximations of chance
constraints.
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An SAA of Chance Constraints: In the SAA method, the true continuous probability function P in (3b) is
approximated by its empirical counterpart PS . To develop PS , we begin by generating a sample {δ1ijt, δ
2
ijt, . . . , δ
S
ijt } of
S independent, identically distributed (iid) realizations of the uncertain parameter ∆ijt . Let ps = 1/S, s = 1, . . . , S be
the probability of each realization. Let Λ(δsijt ) represent a measure of mass 1 at point δ
s
ijt , then, P
S :=
∑S
s=1 psΛ(δ
s
ijt )
(Pagnoncelli et al. 2009).
Let 1(0,∞)(.) : R −→ R be an indicator function such that 1(0,∞)(ℓ) := 1 if ℓ > 0, and 1(0,∞)(ℓ) := 0 if ℓ ≤ 0. Using
this function we derive Problem (Pˆ), which is the deterministic SAA formulation of (P):
(Pˆ) : max
x∈X
F(x) (4a)
s.t.
1
S
S∑
s=1
(1(0,∞)(Gijt (x, δ
s
ijt ))) ≥ (1 − βˆ), ∀i ∈ I, j ∈ J, t ∈ T , (4b)
where βˆ ≥ 0 is different from the risk factor (β) of the original problem. Let υS be the optimal solution to Problem (Pˆ)
and XS be the corresponding feasible region. Luedtke and Ahmed (2008) show that if 1 − βˆ > 1 − β, then every
feasible solution of Problem (Pˆ) is with high probability also feasible for Problem (P) as the number of realizations S
increases. Stated formally, υS −→ υ∗ and XS −→ X w.p.1 as S −→ ∞.
Constraints (4b) use of an indicator function renders them computationally intractable by commercial solvers. We
reformulate these constraints by introducing the continuous variables vijt and wijt , and the penalty term πijt . Variables
vijt and zijt are slack variables that measure violations of constraints (4b). A vijt > 0 indicates a shortage, and a
zijt > 0 indicates excess of vaccine type i at location j in period t. The parameter πijt represents a penalty for not
serving demand in time t. The resulting reformulation of (Pˆ) is
(P¯) : max
x∈X
F(x) −
S∑
s=1
(∑
i∈I
∑
j∈J
∑
t ∈T
πijtv
s
ijt
)
(5a)
s.t. Gijt (x, δ
s
ijt ) + v
s
ijt − z
s
ijt = 0, ∀i ∈ I, j ∈ J, t ∈ T , s = 1, . . . , S, (5b)
v
s
ijt, z
s
ijt ≥ 0, ∀i ∈ I, j ∈ J, t ∈ T , s = 1, . . . , S. (5c)
The values of πijt are not known in advance. Instead, they are adjusted by Algorithm Binary Search Sample
Average Approximation (BS-SAA) in Appendix B so that vs
ijt
= 0 in at least ⌈(1− βˆ)S⌉ of the scenarios, as required by
constraints (3b). If a specific πijt is too high, then the maximization problem would force v
s
ijt
= 0, for all s = 1, . . . , S,
and consequently Gijt (x, δ
s
ijt
) ≥ 0 for all s = 1, . . . , S.
Proposition 1 Algorithm BS-SAA generates a feasible lower bound for problem (P).
Proof: Algorithm BS-SAA iteratively changes the values of πijt , solves (P¯), and counts the number of scenarios
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s ∈ {1, 2, . . . , S} for which vs
ijt
= 0. The algorithm ends when vs
ijt
= 0 in at least ⌈(1 − βˆ)S⌉ + ǫ of the scenarios
generated, where ǫ > 0 (see steps (11) and (13) of the BS-SAA algorithm).
The solution obtained by the algorithmapproaches the optimal solution of (P) as ǫ −→ 0 and S −→ ∞ (Luedtke and Ahmed
2008). Thus, Algorithm BS-SAA provides a lower bound for model (P). 
4 The Case Study and the Experimental Setup
We develop a case study using data from Niger. We first introduce the data sources and describe the structure of the
distribution network. Following that, we detail our experimental setup, which includes a scenario selection procedure
and an evaluation of the stochastic solution’s performance.
4.1 The Case Study: Vaccine Supply Chain of Niger
Figure 1 presents a map of Niger’s major demand areas. Most of the population in Niger resides in the South, near
the border with Nigeria. We identified eight demand regions: Niamey, Tillaberi, Dosso, Maradi, Tahoua, Agadez,
Zinder, and Diffa. Azadi et al. (2018)’s data analysis of the demand for vaccines in these regions makes two important
observations: (i) population size, birth rates, and adult literacy rates can predict the expected demand for vaccines, and
(ii) the demand for vaccines differs among Niger’s different regions. Thus, we use the region-based linear regression
models developed by Azadi et al. (2018) to determine the expected monthly demand for vaccinations in each clinic.
These regression models are fitted to the available data on childhood vaccinations in the different regions of Niger
from 2008 to 2012. We use population size as the independent variable to estimate the expected monthly demand for
vaccination in each region. These data are obtained from the Demographic and Health Surveys (DHS) (ICF 2017).
Since the data are aggregated at the regional level, we divide each region’s demand equally among the clinics of the
region.
The regression functions are of the form ∆¯ijt = µijt + ωijt , where ωijt represents the residual term. This residual
follows a Normal distribution with mean 0 and constant standard deviation, σijt . As a result, the ∆¯ijt follow a Normal
distribution, N(µijt, σijt ). Our numerical experiments only consider ∆¯ijt > 0; thus, we use ∆ijt = max{0, ∆¯ijt }, which
follows the corresponding truncated Normal distribution.
The vaccine distribution network in Niger consists of four tiers (See Figure 2). The government of Niger purchases
vaccines from the UNICEF headquarters in Denmark, and UNICEF uses planes to replenish the inventory of the
central store at Niamey every two months. Vaccines are shipped from the central store to the regional stores in Niamey,
Tillaberi, Dosso, Maradi, Tahoua, Agadez, Zinder, and Diffa every three months via cold trucks. The district stores
pick up vaccines from the regional stores every month via 4 × 4 trucks. The regional store in Tillaberi is currently
non-functional, so the district stores in this region receive vaccines directly from the central store at Niamey. The
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Fig. 1 Niger map with major demand zones.
Fig. 2 Vaccine supply chain in Niger. Adapted from Chen et al. (2014)
clinics pick up vaccines from the district stores monthly using motorcycles, bicycles, or private cars. This network
consists of eight regional stores, 42 district stores, and 695 clinics. The central and regional stores are equipped with
cold rooms. The district stores use chest refrigerators and freezers, and the clinics use smaller refrigerators and/or
freezers. The set of EPI vaccines currently administered in Niger are BCG, tetanus, measles, oral polio, yellow fever,
and DTP. The characteristics of each vaccine are summarized in Table 1 (Chen et al. 2014). We consider a planning
horizon of 12 months.
4.2 Experimental Setup
The BS-SAA algorithm is developed using JuMP programming language. The large-scale linear program for model (P¯)
is solved using Gurobi Solver version 7.0.2. The experiments are implemented using the high-performance computing
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resource at Clemson University (Galen 2019).
The literature measures immunization coverage rates by SRis , which represents the average SR for vaccine type i
under scenario s, and by FICjs, which represents the average percentage of fully immunized children in region j under
scenario s (Chen et al. 2014). These measures are calculated as
SRis =
∑
j∈J
∑
t ∈T(x
R
ijt
+ xF
ijt
)∑
j∈J
∑
t ∈T(∆
s
ijt
)
, ∀i ∈ I, s = 1, . . . , S, (6a)
FIC js = 100
nj∑
i∈I
∑
t ∈T(∆
s
ijt
)
, ∀ j ∈ J, s = 1, . . . , S, (6b)
where nj is the total number of fully immunized children at clinic j, nj ≤
∑
t ∈T(x
R
ijt
+ xF
ijt
)/ai, ∀i ∈ I; and ai is the
number of doses of vaccine i specified by the vaccine regimen.
4.3 Evaluating the BS-SAA Algorithm
Weuse the approach proposed in Luedtke and Ahmed (2008) to identify the sample size S and the number of replications
M to use in our experimental analysis. This approach ensures with high confidence that a solution to model (P¯) is also
a feasible solution of high quality to the original problem (P). Luedtke and Ahmed (2008) show that the confidence
levels for our results are at least 1 −
(
1
2
)M
, so we choose M = 10, which yields 1 −
(
1
2
)10
= 0.999.
Finding a feasible solution (lower bound (LB)): We solve ten iterations (P¯) using a sample of size S. Let x be a
feasible solution to (P¯), and let SR, FIC be the corresponding values of SR and FIC. Next, we conduct a posterior
check using a large sample of size S′. Our posterior check uses this new sample of ∆s
ijt
(s ≤ S′) to recalculate SR and
FIC. These values are compared to SR and FIC. If the difference found is not significant, then we consider x to be a
feasible solution to problem (P).
Because SR measures the percentage of children that can be vaccinated in a clinic using the available inventory,
SR is the probability that demand for vaccination is met, which is equivalent to the chance constraints. Hence our
posterior check focuses on SR.
We solve model (P¯) for a four-tier supply chain using samples of size S = 10, 30, 50, . . . 300. In these experiments,
β = 0.80 and βˆ = 0.70. Note that we could not find feasible solutions for smaller values of βˆ because of the limited
storage capacity. We use S′ = 300 for the posterior analysis. Table 2 summarizes the results of our experiments. All
replications generated feasible solutions. We present the minimum, maximum, and average FIC and SR values of the
solutions, and the average running time. Because increasing the sample size from 250 to 300 has only a marginal
impact on the quality of the solutions, we set S = 300 in the remaining experiments.
Finding an upper bound (UB): To evaluate the quality of our solutions, we solvemodel (P¯) for a four-tier supply chain,
using S = 300 and βˆ = β = 0.80. We find the maximum SR and maximum FIC values across M = 10 replications.
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Table 2 Evaluating the Quality of Feasible Solutions (βˆ = 0.70)
Average SR (%) Average FIC (%) Avg Run
S Min Max Avg Min Max Avg Time (sec)
10 36.68 37.33 36.95 11.67 12.17 12.03 97
30 32.81 33.17 33.03 10.08 10.72 10.48 146
50 30.40 31.03 30.74 8.76 9.24 9.04 163
70 28.28 28.83 28.58 8.05 8.41 8.32 133
100 26.51 26.88 26.66 7.56 7.80 7.73 164
200 24.03 24.17 24.10 6.86 6.99 6.92 202
250 23.44 23.64 23.55 6.71 6.81 6.75 289
300 23.10 23.24 23.17 6.59 6.69 6.63 776
We consider these values to be upper bounds for SR and FIC. Next, we calculate the percentage difference (error gap)
between these values and the feasible solutions presented in Table 2 for S=300. Table 3 demonstrates that our algorithm
results are quite good.
Table 3 Evaluating the Upper Bounds (βˆ = 0.80)
Average SR (%) Average FIC (%)
S Min Max Avg Min Max Avg
300 2.98 3.57 3.28 8.76 10.19 9.58
5 Discussion of Results
Numerical analysis offers answers to the research questions outlined in the introduction section. Our experimental
results are summarized in Figures 3 to 9. These figures present the distribution of FIC and SR via box and whisker
plots. The lines in these plots represent the mean values.
R1: How does changing the number of tiers in the supply chain affect vaccine availability? We evaluate the
impacts on FIC and SR of removing regional stores in Niger’s current four-tier supply chain. In the three-tier supply
chain, the district stores receive shipments from the central store and deliver vaccines to clinics.
We test two scenarios: one in which the cold storage capacity of regional stores is relocated to the district stores,
and one in which the cold storage capacity is equally distributed among clinics. Next, we summarize our observations.
The four-tier supply chain has an average FIC below 10% and a maximum FIC below 22% (see Figure 3a). Thus,
immunization coverage rates are far from the target value of 90% established by the World Health Assembly. Removal
of regional stores leads to higher values of average FIC and SR, assuming the cold storage capacity is reallocated
downstream in the supply chain.
The values of SR and FIC are highest in the three-tier supply chain when cold storage capacity is relocated to clinics.
Notice that the distribution of FIC is right-skewed (see Figure 3b). The mean value of FIC and the corresponding right
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tail is shorter when the capacity is relocated to the district stores (see Figure 3c).
This observation goes against the risk-pooling concept in inventory management, but it is consistent with the work
of Kurata (2014), who studies a supply chainwith a single supplier, multiple retailers and product-availability-conscious
customers (who abandon a given purchase if the items are not available at a given store). Kurata (2014) shows that in
such a system locating inventory at retailers outperforms locating inventory at the supplier. In the environment of our
case study, if a vaccine is not available, a child is not vaccinated. Thus, our patients are product-availability-conscious.
Furthermore, demand across the supply chain is highly correlated, so risk-pooling should be less effective.
In the four-tier supply chain, the average FIC across all regions is 9.5%, and the average SR across all vaccine types
is 30%. A paired t-test at significance level 0.05 indicates that the mean values of both FIC and SR are statistically
better in three-tier supply chains than they are in four-tier supply chains. This observation contradicts the results
presented in Chen et al. (2014).
The largest SR is achieved for oral polio vaccine in four-tier supply chains (Figure 4a). Thus, it has little room for
improvement (Figure 4b) when the supply chain is reduced to three tiers. The reasons for this are that this vaccine (i)
requires four doses to complete the vaccine regimen, so demand for this vaccine is higher than others; (ii) takes less
storage space; and (iii) uses a diluent that does not need refrigeration.
R2: How does vaccine vial size effect immunization coverage rates? We evaluate the impact of manufacturing
vaccines in different vial sizes (i.e., 1-, 5-, and 10-dose vials) on FIC and SR in Niger by extending model (P) to
consider a combination of vaccine vial sizes. The corresponding mathematical model is presented in Appendix C.
We consider two scenarios. The first assumes that only the measles vaccine is distributed in vials of different sizes
(1-, 5-, and 10-doses), and the second assumes that both measles and BCG vaccines are distributed in vials of different
sizes (measles: 1-, 5-, and 10-doses; BCG: 10- and 20-doses). In each scenario, the vial sizes for the remaining vaccine
types are as presented in Table 1.
Using a combination of different sized vials does not lead to statistically significant improvements of FIC in LMI
countries with limited cold supply chain capacity (compare Figures 3a and 5a). The percentages of FIC in different
regions do not change because, even though using a combination of vials of different sizes leads to lower OVW and
improved vaccine availability (Azadi et al. 2019), using a combination of sizes requires additional refrigeration space.
The results from both scenarios support this observation.
The improvements in SR when only the measles vaccine is distributed in vials of different sizes are not statistically
significant (see Figures 4a and 5b). However, there is a statistically significant improvement in SR when both measles
and BCG vaccines are distributed in vials of different sizes (Scenario 2). Figure 6 indicates a 2% increase in the mean
value of SR for the polio vaccine when combinations of sizes are used for both measles and BCG. A paired t-test at
significance level 0.05 shows that this difference is statistically significant. A 2% increase in vaccine availability can
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potentially immunize an additional 20, 000 children.
R3: How does using new vaccine presentations affect immunization coverage rates? To evaluate the impacts of
using dual-chamber and thermostable vaccines on FIC and SR in Niger, consider two scenarios. In the first, replace
regular measles vaccines with dual-chamber injection devices. In the second, replace one of the EPI vaccines with a
thermostable vaccine, which requires no cold storage space.
The difference in the mean distribution of FIC and SR for measles between using a single-dose dual-chamber
injection device and using ten-dose vials of measles vaccine (the current implementation) is statistically insignificant
(compare Figure 7 to Figure 3a and Figure 4a). This finding also holds when comparing a single-dose dual-chamber
injection device to a single-dose standard vial. These results are confirmed via a paired t-tests at a significance level
of 0.05.
Using a dual-chamber vaccine consumes more of the limited storage space, but it also reduces OVW. Thus, the
compound effect led to a slight reduction in FIC and SR.
The country-based FIC of Niger could almost double if the classically available DTP-HepB-Hib vaccines are
substituted with thermostable vaccines (Figure 8 shows that the average FIC is 6% if no thermostable vaccine is used).
Each vial of DTP-HepB-Hib vaccine contains only one dose, and its packed volume is the largest among all vaccine
types, so using thermostable vaccines would free much cold storage space that can be used for other vaccines.
Comparing Figure 4a and Figure 9 yields the following conclusions about the effects of using a thermostable
formulation for a single vaccine.
• Using a thermostable DTP-HepB-Hib vaccine increases the mean value of SR for every vaccine but polio (Figure
9a). This small decrease of polio’s SR arose from the increase in the total number of children vaccinated, which
is the denominator φs
j
in the definition of SR (Equation (6b)), and from polio’s high original SR.
• Using a thermostable oral polio vaccine increases the correspondingmean value of its SR to 100%. Additionally,
the mean value of SR for BCG increases by close to three times (Figure 9b). The SR values for the remaining
vaccines do not change.
• Using a thermostable tetanus vaccine increases the corresponding mean value of its SR by close to four times.
Additionally, this increases the mean values of SR for BCG and YF by 4%, and the mean values for both
DTP-HepB-Hib and measles by 8% (Figure 9d).
• Using a thermostable YF vaccine increases the correspondingmean value of its SR by close to four times (Figure
9e). The SR values for the remaining vaccines do not change.
• Using a thermostable measles vaccine increases the mean of SR for every vaccine except oral polio (Figure 9f).
Recommendations: These observations lead to the following recommendations:
We recommend that public health authorities invest to increase cold storage capacity (i.e., cold rooms, refrigerators,
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and freezers) of clinics because this is the bottleneck in this supply chain, so these investments would directly lead to
improved immunization coverage. Countries with limited resources should prioritize cold storage and distribution for
those vaccines with the highest number of doses required by vaccine regimen (i.e., polio) because the availability of
these vaccines has the greatest influence on SR. Niger exemplifies the benefit of this practice by having a very high SR
for the oral polio vaccine.
We recommend that public health authorities evaluate the trade-offs among OVW, FIC, and SR when considering
changes to vaccine packaging. Our numerical analysis indicates that the use of a combination of vials of different sizes
of the same vaccine leads to reduced OVW, but may not necessarily lead to more FIC and higher SR for every vaccine
type in LMI countries with limited storage capacity in the cold supply chain.
We recommend that public health authorities evaluate the trade-offs among vaccine presentation, storage space
required, vaccine availability, and waste from OVW when they consider using new vaccine technologies, such as
dual-chamber and thermostable vaccines. This is especially relevant in countries that have limited resources because
new technologies are expensive and may require additional storage space.
We do not recommend the use of dual-chamber vaccines. They require additional cold storage space per dose
because the diluent in a dual-chamber vaccine is attached to the vaccine (the diluent of a regular vaccine does not need
refrigeration). Hence, their use reduces the availability of all vaccines. These problems greatly outweigh dual-chamber
vaccines’ zero OVW and ease of administration.
Thermostable vaccines reduce waste by consuming less cold storage space. Thus, they increase immunization
coverage. However, thermostable vaccines are expensive, so public health authorities in LMI countries should use their
limited resources strategically by investing in thermostable vaccines that have the greatest impact on immunization
coverage. Therefore, we recommend vaccines that require large storage capacity per dose, such as DTP-Hep-Hib, have
thermostable formulations.
6 Conclusions and Future Research
Public health officials in low- and middle-income (LMI) countries have historically used educational campaigns to
teach the importance of vaccination and increase participation. These campaigns are a good first step, but their success
depends on the efficiency of the vaccine supply chain to deliver EPI (Expanded Program on Immunization of theWorld
Health Organization) vaccines to clinics. Thus, public health officials need tools that evaluate their decisions’ impacts
on the performance of the supply chain. Such evaluations could guide public policies that improve immunization
coverage rates.
We develop a stochastic optimization model that captures the uncertainty of demand for vaccination via chance
constraints. To the best of our knowledge, this study is the first to apply a stochastic optimization model to evaluate the
impact of supply chain decisions on LMI countries’ immunization coverage rates, as measured by the proportion of
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fully immunized children (FIC) and the supply ratio (SR) for a case study using data from Niger. The specific supply
chain issues examined are the supply chain design, the vaccine packaging, and the vaccine presentation.
We conduct a comprehensive analysis of the effects that the following supply chain decisions have on immunization
coverage rates: (i) redesigning the supply chain from a four- to a three-tier supply chain by removing the regional
stores; (ii) distributing a combination of vaccine vials with different sizes; and (iii) using new technologies, such as
dual-chamber injection devices and thermostable vaccines. Our main observations are
1) Streamlining the supply chain by removing regional stores leads to higher values of average FIC and SR if the
cold storage capacity is reallocated to the clinics.
2) In LMI countries with limited cold supply chain resources, using a combination of vials of different sizes for
one vaccine leads to reduced open vial wastage (OVW) but may not necessarily lead to increased FIC and SR.
3) Public health officials need to understand the trade-offs between vaccine availability and the waste from OVW
when considering the use of dual-chamber vaccines. This is especially relevant in countries that have limited
resources because dual-chambervaccines require additional storage space per vial, which reduces the availability
of all vaccines.
4) Using thermostable vaccines reduces waste and therefore increases immunization coverage. Thermostable
vaccines are expensive, but public health authorities in LMI countries can use their limited resources strategically
by investing in this technology for those vaccines for which doing so will cause the greatest increase in
immunization coverage. For example, DTP-Hep-Hib (diphtheria, tetanus, pertussis, hepatitis B and haemophilus
influenza) requires large storage capacity per dose, so substituting DTP-Hep-Hib with a thermostable vaccine
would reduce waste and release the cold storage space to other vaccines.
As with other studies of humanitarian supply chains that focus onminimizing the delivery time of essential supplies,
minimizing stock-outs, maximizing the number of people served, etc., this study does not explicitly focus on costs.
Reductions of supply chain costs, which are funded by non-profit organizations (World Health Organization, World
Bank, United Nations Children’s Fund, etc.) and the local government, clearly would lead to savings that could be used
to extend cold storage capacity. Thus, we plan to extend this analysis to consider the economic impacts of the supply
chain decisions discussed in this paper.
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Appendices
Appendix A Chance-constrained programming model
The problem parameters and decision variables are presented as follows: Figure 10 provides a schematic representation
of our modeling a three-tier vaccine supply chain with one central store, two district stores, and one clinic that uses
only refrigerators for storing vaccines. This network considers one vaccine type and two time periods. The nodes in
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successive time periods are connected to represent the flow of inventory. Inventory arcs are represented by the dotted
lines. The solid arcs represent transportation decisions.
Set of Indices:
I: Set of vaccine types.
IR: Set of vaccines that can only be stored in a refrigerator. IR ⊂ I.
J : Set of the nodes in the network.
T : Set of periods in the planning horizon.
Parameters:
µijt : Mean demand for doses of vaccine type i at location j in time period t.
µ′
ij
: Mean daily demand for doses of vaccine type i at location j.
ωijt : Uncertain parameter representing the demand for doses of vaccine type i at location j in time period t.
CR
j
: Effective refrigerator capacity at location j.
CF
j
: Effective freezer capacity at location j.
CV
k j
: Effective transport capacity from location k to location j.
qi: Effective packed volume of one dose of vaccine i.
ri: Diluent volume for vaccine i.
ai: Number of doses administered of vaccine i within the vaccine regimen.
β: Risk factor.
w
R
ijt
: Fraction of vaccine i inventory in refrigerators lost at location j in period t.
w
F
ijt
: Fraction of vaccine i inventory in freezers lost at location j in period t.
w
RR
ik jt
: Fraction of vaccine i going from a refrigerator at location k to a refrigerator at location j in time period t that is
lost.
w
RF
ik jt
: Fraction of vaccine i going from a refrigerator at location k to a freezer at location j in time period t that is lost.
w
FR
ik jt
: Fraction of vaccine i going from a freezer at location k to a refrigerator at location j in time period t that is lost.
w
FF
ik jt
: Fraction of vaccine i going from a freezer at location k to a freezer at location j in time period t that is lost.
w
O
ijt
: Fraction of OVW for vaccine i at location j in time period t.
ε: Positive constant used to normalize the second term in the objective.
Decision variables:
xR
ijt
: Units of vaccine i from a refrigerator that satisfy demand at location j in period t.
xF
ijt
: Units of vaccine i from a freezer that satisfy demand at location j in period t.
nj : Number of FIC at location j.
IR
ijt
: Inventory of vaccine i in a refrigerator at location j at the end of time period t.
IF
ijt
: Inventory of vaccine i in a freezer at location j at the end of time period t.
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SRR
ik jt
: Units of vaccine i shipped from a refrigerator at location k to a refrigerator at location j in time period t.
SRF
ik jt
: Units of vaccine i shipped from a refrigerator at location k to a freezer at location j in time period t.
SFR
ik jt
: Units of vaccine i shipped from a freezer at location k to a refrigerator at location j in time period t.
SFF
ik jt
: Units of vaccine i shipped from a freezer at location k to a freezer at location j in time period t.
A planning model for the vaccine distribution network is formulated as the following chance-constrained program:
4max
∑
j∈J
nj + ε
∑
i∈I
∑
j∈J
∑
t ∈T
(xRijt + x
F
ijt ), (7a)
s.t.
IRijt = (1 − w
R
ijt−1)I
R
ijt−1 +
∑
k∈J,k,j
(1 − wFRik jt−1)S
FR
ik jt−1 +
∑
k∈J,k,j
(1 − wRRik jt−1)S
RR
ik jt−1
−
∑
k∈J,k,j
SRFijkt −
∑
k∈J,k,j
SRRijkt −
xR
ijt
(1 − wO
ijt
)
∀i ∈ I, j ∈ J, t ∈ T \ {0}, (7b)
IFijt = (1 − w
F
ijt−1)I
F
ijt−1 +
∑
k∈J,k,j
(1 − wRFik jt−1)S
RF
ik jt−1 +
∑
k∈J,k,j
(1 − wFFik jt−1)S
FF
ik jt−1
−
∑
k∈J,k,j
SFRijkt −
∑
k∈J,k,j
SFFijkt −
xF
ijt
(1 − wO
ijt
)
∀i ∈ I, j ∈ J, t ∈ T \ {0}, (7c)
∑
i∈I
qi
(
IRijt +
∑
k∈J,k,j
(1 − wFRik jt )S
FR
ik jt +
∑
k∈J,k,j
(1 − wRRik jt )S
RR
ik jt
)
≤ CRj −
∑
i∈I
ri µ
′
ij ∀ j ∈ J, t ∈ T , (7d)
∑
i∈I
qi
(
IFij +
∑
k∈J,k,j
(1 − wRFik jt )S
RF
ik jt +
∑
k∈J,k,j
(1 − wFFik jt )S
FF
ik jt
)
≤ CFj ∀ j ∈ J, t ∈ T , (7e)
IRij0 = 0 ∀i ∈ I, j ∈ J, (7f)
IFij0 = 0 ∀i ∈ I, j ∈ J, (7g)
IF
ij |T |
= 0 ∀i ∈ IR, j ∈ J, (7h)
∑
i∈I
qi(S
RR
ik jt + S
RF
ik jt + S
FR
ik jt + S
FF
ik jt ) ≤ C
V
k j
∀ j, k ∈ J ; j , k, t ∈ T , (7i)
nj ≤
∑
t ∈T
(xRijt + x
F
ijt )/ai ∀i ∈ I, j ∈ J, (7j)
Pr
(
xRijt + x
F
ijt ≥ ∆ijt
)
≥ β ∀i ∈ I, j ∈ J, t ∈ T , (7k)
x
R/F
ijt
, nj, I
R/F
ijt
, S
RR/RF/FR/FF
ik jt
≥ 0 ∀i ∈ I, j, k ∈ J ; j , k, t ∈ T . (7l)
In this model, the first term in the objective function maximizes the percentage of FIC over all clinics. This results
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in maximizing the number of children who receive the required doses specified by the vaccine regimen. The second
term presents the total number of doses delivered to clinics, which impacts SR. Since these two terms have different
units, we normalize the second term by multiplying it with a coefficient ε ∈ [0, 1]. By varying the value of this
coefficient one can give more or less relative weight to maximizing the percentage of FIC.
Equations (7b) and (7c) are the inventory balance constraints for refrigerators and freezers at each facility in the
supply chain. It is assumed that the lead time for shipping vaccines between successive tiers of the supply chain, is one
week. The model accounts for specific shipment schedules between locations j and k by fixing variables SRR
ik jt
, SRF
ik jt
,
SFR
ik jt
, and SFF
ik jt
to 0 during time periods when there are no shipments. Doing this allows us to model realistic situations,
such as a schedule that delivers vaccines from the central to regional stores every three months.
Constraints (7d) and (7e) limit the storage capacity of refrigerators and freezers, respectively. We adjust the
refrigerator capacity in (7d) to account for the fact that diluents are refrigerated before vaccination. Constraints (7f)
and (7g) initialize the inventory of vaccines in refrigerators and freezers, respectively. Constraints (7h) guarantee
that vaccines that are not stable at freezer temperature must only be stored in refrigerators. Constraint (7i) limits the
transportation capacity between two locations. Note that the model assumes both freezable and non-freezable vaccines
are shipped via the same vehicle type. Constraint (7j) determines FIC for each location. The right hand side of this
inequality represents the average number of individuals to whom a full set of doses of vaccine i is administered at
clinic j over the planning horizon, which is found by dividing the total number of vaccine i doses administered by the
number of required doses defined in the vaccine regimen at clinic j. Therefore, FIC is bounded by the smallest value
among all vaccine types.
Finally, (7k) is a chance constraint that indicates the total number of vaccine type i delivered to clinic j in period
t should be greater than the total demand for vaccines at least β ∗ 100% of the time. This constraint captures the
random nature of patient arrivals. This constraint also indicates that some times, the children present at a clinic are not
vaccinated if there is no inventory or if the session size is small.
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Appendix B BS-SAA algorithm
Algorithm 1 BS-SAA Algorithm
Notation: Let πL
ijt
and πU
ijt
denote the lower and upper bounds of the penalty term πijt . Also, let ǫ and ϑ be small
positive constants (δ = σ = 0.01).
1: while |πijt −
pi
L
i jt
+pi
U
i jt
2
| > ϑ ∀i ∈ I, j ∈ J, t ∈ T do
2: πijt ←
pi
L
i jt
+pi
U
i jt
2
3: Solve (P¯) and let vˆs
ijt
, be the incumbent solution of vs
ijt
, ∀i ∈ I, j ∈ J, t ∈ T .
4: for i ∈ I, j ∈ J, t ∈ T do
5: Mijt ← 0
6: for s = 1, . . . , S do
7: if vˆs
ijt
< 0 then
8: Mijt ← Mijt + 1
9: end if
10: end for
11: if Mijt ≤ (⌈1 − βˆ⌉S) + ǫ then
12: πL
ijt
←
pi
L
i jt
+pi
U
i jt
2
13: else if Mijt ≥ (⌈1 − βˆ⌉S) − ǫ then
14: πU
ijt
←
pi
L
i jt
+pi
U
i jt
2
15: end if
16: end for
17: end while
18: Return πijt, ∀i ∈ I, j ∈ J, t ∈ T , and the solution to (P¯)
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Appendix C Extended chance-constrained programming model
To extend model in (7), a new set N i is introduced to denote different sizes of the vaccine type i. Note that vial size
refers to the number of doses per vial. Moreover, a superscript ι is introduced to denote the size of the vaccine.
The new problem parameters and decision variables are presented as follows:
Set of Indices:
I: Set of vaccine types.
N i : Set of available vial sizes for vaccines type i.
IR: Set of vaccines that can only be stored in a refrigerator. IR ⊂ (I × N i).
J : Set of the nodes in the network.
T : Set of periods in the planning horizon.
Parameters:
µijt : Mean demand for doses of vaccine type i at location j in time period t.
µ′
ij
: Mean daily demand for doses of vaccine type i at location j.
ωijt : Uncertain parameter which represents the demand for doses of vaccine type i at location j in time period t.
CR
j
: Effective refrigerator capacity at location j.
CF
j
: Effective freezer capacity at location j.
CV
k j
: Effective transport capacity from location k to location j.
qι
i
: Effective packed volume of one dose of vaccine type i of vial size ι.
r ι
i
: Diluent volume for vaccine type i of vial size ι.
ai: Number of doses administered of vaccine type i within the vaccine regimen.
bι
i
: Number of doses per vial for vaccine type i of size ι.
β: Risk factor.
w
Rι
ijt
: Fraction of vaccine type i of size ι inventory in refrigerators lost at location j in period t.
w
F ι
ijt
: Fraction of vaccine type i of size ι inventory in freezers lost at location j in period t.
w
RRι
ik jt
: Fraction of vaccine type i of size ι going from a refrigerator at location k to a refrigerator at location j in time
period t that is lost.
w
RF ι
ik jt
: Fraction of vaccine type i of size ι going from a refrigerator at location k to a freezer at location j in time period
t that is lost.
w
FRι
ik jt
: Fraction of vaccine type i of size ι going from a freezer at location k to a refrigerator at location j in time period
t that is lost.
w
FF ι
ik jt
: Fraction of vaccine type i of size ι going from a freezer at location k to a freezer at location j in time period t
that is lost.
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w
Oι
ijt
: Fraction of OVW for vaccine type i of size ι at location j in time period t.
ε: Positive constant used to normalize the second term in the objective.
Decision variables:
xRι
ijt
: Units of vaccine type i of size ι used from a refrigerator to satisfy demand at location j in period t.
xF ι
ijt
: Units of vaccine type i of size ι used from a freezer to satisfy demand at location j in period t.
nj : Number of FIC at location j.
IRι
ijt
: Inventory of vaccine type i of size ι in a refrigerator at location j at end of time period t.
IF ι
ijt
: Inventory of vaccine type i of size ι in a freezer at location j at end of time period t.
SRRι
ik jt
: Units of vaccine type i of size ι shipped from a refrigerator at location k to a refrigerator at location j in time
period t.
SRF ι
ik jt
: Units of vaccine type i of size ι shipped from a refrigerator at location k to a freezer at location j in time period
t.
SFRι
ik jt
: Units of vaccine type i of size ι shipped from a freezer at location k to a refrigerator at location j in time period
t.
SFF ι
ik jt
: Units of vaccine type i of size ι shipped from a freezer at location k to a freezer at location j in time period t.
Here is the extended model formulated for the chance-constrained program in Appendix A:
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max
∑
j∈J
nj + ε
∑
i∈I
∑
j∈J
∑
t ∈T
( ∑
ι∈Ni
(xRιijt + x
F ι
ijt )
)
, (8a)
s.t.
IRιijt = (1 − w
Rι
ijt−1)I
Rι
ijt−1 +
∑
k∈J,k,j
(1 − wFRιik jt−1)S
FRι
ik jt−1 +
∑
k∈J,k,j
(1 − wRRιik jt−1)S
RRι
ik jt−1
−
∑
k∈J,k,j
SRF ιijkt −
∑
k∈J,k,j
SRRιijkt −
xRι
ijt
(1 − wOι
ijt
)
∀i ∈ I, ι ∈ N i, j ∈ J, t ∈ T \ {0}, (8b)
IF ιijt = (1 − w
F ι
ijt−1)I
F ι
ijt−1 +
∑
k∈J,k,j
(1 − wRF ιik jt−1)S
RF ι
ik jt−1 +
∑
k∈J,k,j
(1 − wFF ιik jt−1)S
FF ι
ik jt−1
−
∑
k∈J,k,j
SFRιijkt −
∑
k∈J,k,j
SFF ιijkt −
xF ι
ijt
(1 − wOι
ijt
)
∀i ∈ N, ι ∈ N i, j ∈ J, t ∈ T \ {0}, (8c)
∑
i∈I
∑
ι∈Ni
qιib
ι
i
(
IRιijt +
∑
k∈J,k,j
(1 − wFRι
ik jt
)SFRι
ik jt
+
∑
k∈J,k,j
(1 − wRRι
ik jt
)SRRι
ik jt
)
≤ CRj −
∑
i∈I
ri µ
′
ij ∀ j ∈ J, t ∈ T , (8d)
∑
i∈I
∑
ι∈Ni
qιib
ι
i
(
IF ιij +
∑
k∈J,k,j
(1 − wRF ιik jt )S
RF ι
ik jt +
∑
k∈J,k,j
(1 − wFF ιik jt )S
FF ι
ik jt
)
≤ CFj ∀ j ∈ J, t ∈ T , (8e)
IRιij0 = 0 ∀i ∈ I, ι ∈ N
i, j ∈ J, (8f)
IF ιij0 = 0 ∀i ∈ I, ι ∈ N
i, j ∈ J, (8g)
IF ι
ij |T |
= 0 ∀i ∈ IR, ι ∈ N i, j ∈ J, (8h)
∑
i∈N
∑
ι∈Ni
qιib
ι
i(S
RRι
ik jt + S
RF ι
ik jt + S
FRι
ik jt + S
FF ι
ik jt ) ≤ C
V
k j
∀ j, k ∈ J ; j , k, t ∈ T , (8i)
nj ≤
∑
t ∈T
∑
ι∈Ni
bιi(x
Rι
ijt + x
F ι
ijt )/ai ∀i ∈ I, j ∈ J, (8j)
Pr
( ∑
ι∈Ni
bιi(x
Rι
ijt + x
F ι
ijt ) ≥ ∆ijt
)
≥ β ∀i ∈ I, j ∈ J, t ∈ T , (8k)
x
R/F ι
ijt
, nj, I
R/F ι
ijt
, S
RR/RF/FR/FF ι
ik jt
≥ 0 ∀i ∈ I, ι ∈ N i, j, k ∈ J ; j , k, t ∈ T . (8l)
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Fig. 3 (a) Region-Based FIC for Four-Tier Supply Chain; (b) % Increase in FIC in a Three-Tier Supply Chain
if capacity is added to Clinics; (c)% Increase in FIC in a Three-Tier Supply Chain if capacity is added to District
Stores.
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Fig. 4 (a) Vaccine-Based SR for Four-Tier Supply Chain; (b) % Increase in SR in a Three-Tier Supply Chain
if capacity is added to Clinics; (c) % Increase in SR in a Three-Tier Supply Chain if capacity is added to District
Stores.
32
Agadez Diffa Dosso Maradi Tillaberi Tahoua Zinder Niamey
Region
0
5
10
15
20
25
30
35
Pe
rc
en
ta
ge
 o
f F
IC
(%
)
(a) FIC
Or
al P
olio BC
G
Ye
llow
 Fe
ve
r
Te
tan
us
DT
P-H
ep
B-H
ib
Me
as
les
-10
do
se
Me
as
les
-5d
os
e
Me
as
les
-1d
os
e
Vaccine
0
10
20
30
40
50
60
70
80
Su
pp
ly 
Ra
tio
(%
)
(b) SR
Fig. 5 Scenario 1: region-based FIC and vaccine-based SR.
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Fig. 6 Scenario 2: SR of oral polio vaccine for single and multiple vial sizes.
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Fig. 7 Region-based FIC and vaccine-basedSR for a four-tier supply chainwith dual-chambermeasles vaccine.
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Fig. 8 Country-Based FIC if the labeled Vaccine Is Thermostable.
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Fig. 9 Vaccine-based SR: the vaccine in a panel’s caption is thermostable.
35
hFig. 10 A vaccine supply chain distribution network with three tiers: 1 central store, 2 district stores, and 1
clinic.
36
